Drug Trial Radar · NCT04643249
Drug-drug Interaction Study of KL1333 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Oct 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Nov 10, 2020
Primary completion
Dec 17, 2020
Study completion Dec 17, 2020
Sponsor
- Lead sponsor
- Abliva ABIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects
Conditions
- Mitochondrial Disease
Interventions
KL1333Drug
Tablet
FlurbiprofenDrug
Tablet
DextromethorphanDrug
Syrap
BupropionDrug
Tablet
Midazolam injectionDrug
solution for injection
OmeprazoleDrug
Capsule
CaffeineDrug
Tablet or capsule
RepaglinideDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of the effect of KL1333 on the PK of repaglinide, caffeine, omeprazole, midazolam, bupropion, dextromethorphan, and flurbiprofen in healthy subjects.Time frame: day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Volunteer recruitment center Covance Leeds Covance Leeds
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.